There is growing evidence that SARS-CoV-2 can damage organs beyond lung, including heart, blood vessels, immune cells, kidney and even neural tissue. Limited understanding of the impact of SARS-CoV-2 on such tissues limits our capacity to treat patients optimally and anticipate long term complications. This collaborative program will generate a wide variety of stem cell-derived human tissues to study viral infection and impact on comorbidities. This will increase our understanding of disease pathology, change clinical care and facilitate the development of targeted treatment options.
|Effective start/end date||16/09/20 → 15/09/21|